How AOD-9604 Works at the Molecular Level AOD-9604 mimics the lipolytic (fat-burning) region of human growth hormone without binding to growth hormone receptors
BPC-157 for tendon injury is administered subcutaneously near the affected tendon
The further synergistic combination approach with other gastrointestinal hormones and creation of dual GIP/GLP-1 receptor agonists, such as tirzepatide and GLP-1/GIP/glucagon receptor triagonist, retatrutide, has shown unprecedented pharmacologically achieved weight loss with further cardiometabolic benefits in both obesity and T2DM
Beyond cellular senescence, FOXO4-DRI demonstrates promise in neuroprotection, muscle regeneration, and cardiovascular health, positioning it as a keystone compound in longevity medicine (5, 6, 7)
Journal of Tissue Engineering 15:20417314241303818